PMID- 18677926
OWN - NLM
STAT- MEDLINE
DCOM- 20080924
LR  - 20151119
IS  - 0048-7848 (Print)
IS  - 0048-7848 (Linking)
VI  - 112
IP  - 1
DP  - 2008 Jan-Mar
TI  - Flow cytometry-based quantification of cytokine levels in AML patients plasma and 
      cell culture supernatants.
PG  - 196-202
AB  - AIM: Bone marrow stromal cells (BMSCs) have been found to support leukemic cell 
      survival; however, the mechanisms responsible are far from being elucidated yet. 
      The main aim of the current study is to identify particular cytokine/chemokine 
      patterns of acute myeloid leukemia (AML) cells, and, on a longer term, to 
      correlate them with the patient outcome and response to therapy. Therefore, the 
      influence of BMSCs on in vitro modulation of cytokine secretion (IL-1beta, 
      TNF-alpha, IL-10, IFN-gamma, IL-4, IL-5, and IL-2) by AML cells as well as the 
      AML cells supportive capacity of BMSCs-derived soluble factors was investigated. 
      MATERIAL AND METHODS: With this purpose, we used an in vitro experimental model 
      consisting in the evaluation of the effect of BMSC confluent layers-conditioning 
      medium (BMSC-CM) on M4/5 AML cell cultures. RESULTS: Our results show that 
      BMSC-CM from both AML patients and healthy subjects conferred a substantial 
      beneficial effect on AML cells throughout the culture (p=0.0002 and 0.0020 
      respectively at 24 hours and p=0,0013 and 0,0030 respectively at 72 hours), with 
      a temporary increase in AML cell viability conferred by BM plasma from AML 
      patients. Significant differences were observed with respect to IL1 b secretion 
      which was upregulated in AML cell cultures both after 24 and 72 hours following 
      the addition of AML-BMSC-CM, in contrast to control-BMSC-CM. CONCLUSION: Our 
      results suggest the contribution of BMSCs from AML patients to the generation of 
      particular factors which may be key players involved in the in vivo maintenance 
      of the malignant clone.
FAU - Dacalescu, Angela
AU  - Dacalescu A
AD  - Gr.T. Popa University of Medicine and Pharmacy Iasi, School of Medicine, 
      Department of Hematology.
FAU - Zlei, Mihaela
AU  - Zlei M
FAU - Aanei, Carmen
AU  - Aanei C
FAU - Ungureanu, Didona
AU  - Ungureanu D
FAU - Tepelus, Maria
AU  - Tepelus M
FAU - Burcoveanu, Cristina
AU  - Burcoveanu C
FAU - Danaila, C
AU  - Danaila C
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Romania
TA  - Rev Med Chir Soc Med Nat Iasi
JT  - Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi
JID - 0413735
RN  - 0 (Antiviral Agents)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Chemokines)
RN  - 0 (Cytokines)
RN  - 0 (IL-10-related T cell-derived inducible factor, IL-TIF)
RN  - 0 (Interleukin-2)
RN  - 0 (Interleukin-5)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 130068-27-8 (Interleukin-10)
RN  - 207137-56-2 (Interleukin-4)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Antiviral Agents/analysis
MH  - Biomarkers, Tumor/*analysis
MH  - Bone Marrow Cells/*metabolism
MH  - Chemokines/analysis
MH  - Cytokines/*analysis/blood
MH  - *Flow Cytometry/methods
MH  - Humans
MH  - In Vitro Techniques
MH  - Interferon-gamma/analysis
MH  - Interleukin-10/analysis
MH  - Interleukin-2/analysis
MH  - Interleukin-4/analysis
MH  - Interleukin-5/analysis
MH  - Leukemia, Myeloid, Acute/blood/*metabolism
MH  - Tumor Cells, Cultured
MH  - Tumor Necrosis Factor-alpha/analysis
EDAT- 2008/08/06 09:00
MHDA- 2008/09/25 09:00
CRDT- 2008/08/06 09:00
PHST- 2008/08/06 09:00 [pubmed]
PHST- 2008/09/25 09:00 [medline]
PHST- 2008/08/06 09:00 [entrez]
PST - ppublish
SO  - Rev Med Chir Soc Med Nat Iasi. 2008 Jan-Mar;112(1):196-202.